WO2022143675A1 - 用于扩增并维持HSCs自我更新能力和分化潜能的培养基组合物及其应用 - Google Patents
用于扩增并维持HSCs自我更新能力和分化潜能的培养基组合物及其应用 Download PDFInfo
- Publication number
- WO2022143675A1 WO2022143675A1 PCT/CN2021/142127 CN2021142127W WO2022143675A1 WO 2022143675 A1 WO2022143675 A1 WO 2022143675A1 CN 2021142127 W CN2021142127 W CN 2021142127W WO 2022143675 A1 WO2022143675 A1 WO 2022143675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hscs
- cells
- growth factor
- concentration
- pdgfr
- Prior art date
Links
- 230000004069 differentiation Effects 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 239000001963 growth medium Substances 0.000 title claims abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract description 252
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 237
- 239000003112 inhibitor Substances 0.000 claims abstract description 94
- 150000003384 small molecules Chemical class 0.000 claims abstract description 61
- 238000000338 in vitro Methods 0.000 claims abstract description 44
- 239000006143 cell culture medium Substances 0.000 claims abstract description 11
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims abstract 10
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims abstract 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 114
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 114
- 239000003102 growth factor Substances 0.000 claims description 72
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 62
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 45
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 39
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 39
- 239000013028 medium composition Substances 0.000 claims description 34
- 210000004700 fetal blood Anatomy 0.000 claims description 32
- 210000005259 peripheral blood Anatomy 0.000 claims description 32
- 239000011886 peripheral blood Substances 0.000 claims description 32
- 239000003978 infusion fluid Substances 0.000 claims description 26
- 239000007640 basal medium Substances 0.000 claims description 25
- 239000002609 medium Substances 0.000 claims description 23
- 108090001005 Interleukin-6 Proteins 0.000 claims description 19
- 210000001185 bone marrow Anatomy 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 210000000601 blood cell Anatomy 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 12
- WWOXKWLDMLMYQY-UHFFFAOYSA-N 1-n'-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxyphenyl]-1-n-phenylcyclopropane-1,1-dicarboxamide Chemical compound C1=NN(C)C=C1C1=CC(OC=2C(=CC(NC(=O)C3(CC3)C(=O)NC=3C=CC=CC=3)=C(F)C=2)F)=CC=N1 WWOXKWLDMLMYQY-UHFFFAOYSA-N 0.000 claims description 11
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 11
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 11
- NVRXTLZYXZNATH-UHFFFAOYSA-N PP121 Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)C=2C(N)=NC=NC=2N1C1CCCC1 NVRXTLZYXZNATH-UHFFFAOYSA-N 0.000 claims description 11
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 claims description 11
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 11
- 229960003005 axitinib Drugs 0.000 claims description 11
- 229950004444 erdafitinib Drugs 0.000 claims description 11
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 11
- 229960002411 imatinib Drugs 0.000 claims description 11
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 claims description 11
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 11
- 229960001131 ponatinib Drugs 0.000 claims description 11
- 229960000363 trapidil Drugs 0.000 claims description 11
- 238000010362 genome editing Methods 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 108091008606 PDGF receptors Proteins 0.000 description 53
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 53
- 239000006285 cell suspension Substances 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 18
- 102100034195 Thrombopoietin Human genes 0.000 description 18
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 238000002054 transplantation Methods 0.000 description 16
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 10
- 210000001772 blood platelet Anatomy 0.000 description 9
- 210000002798 bone marrow cell Anatomy 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 8
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 7
- 238000010195 expression analysis Methods 0.000 description 7
- 102000056982 human CD33 Human genes 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 6
- 229940105423 erythropoietin Drugs 0.000 description 6
- 102000049018 human NCAM1 Human genes 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 5
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000002960 bfu-e Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000003013 erythroid precursor cell Anatomy 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- -1 small molecule compounds Chemical class 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011773 genetically engineered mouse model Methods 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 210000000777 hematopoietic system Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 230000003021 clonogenic effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011419 induction treatment Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 210000004892 erythrocyte colony-forming unit Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006148 magnetic separator Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000001395 Acute radiation syndrome Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000932480 Homo sapiens Fms-related tyrosine kinase 3 ligand Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010068142 Radiation sickness syndrome Diseases 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Definitions
- the invention relates to the technical field of biotechnology, in particular to a medium composition for expanding and maintaining the self-renewal ability and differentiation potential of HSCs, an infusion solution containing HSCs, and applications thereof.
- Hematopoietic stem cells are a group of heterogeneous primitive hematopoietic cells in the blood system, with two important characteristics of self-renewal and multi-lineage differentiation.
- the HSCs in the body are in a quiescent state for a long time.
- the HSCs are activated and enter a state of self-renewal and multi-lineage differentiation to maintain the stability of the blood system and the body's homeostasis.
- HSCs The self-renewal properties of HSCs are beneficial to the maintenance of stemness of progeny HSCs, while the multi-lineage differentiation properties of HSCs allow them to differentiate into a variety of mature blood cells, such as myeloid cells (granulocytes, monocytes, erythrocytes and platelets), lymphoid cells ( T cells and B cells). It is because of the characteristics of HSCs and their ability to migrate and homing in the blood system that it is beneficial for HSCs to differentiate when the body needs them, and to homing to the bone marrow microenvironment to function when the body is stable.
- myeloid cells granulocytes, monocytes, erythrocytes and platelets
- lymphoid cells T cells and B cells
- HSCs hematopoietic stem cell transplantation
- Thomas et al. used bone marrow hematopoietic stem cells for the first hematopoietic stem cell transplantation in human history to treat leukemia in clinical to restore normal hematopoietic function in patients.
- hematopoietic stem cell transplantation has not only been used to treat a variety of blood system diseases, but also used to treat immunodeficiency diseases and neurodegenerative diseases.
- HSCs bone marrow
- mPB mobilized peripheral blood
- CB umbilical cord blood
- the three sources of HSCs have their own advantages and disadvantages, such as the collection of bone marrow-derived hematopoietic stem cells, which is invasive and insufficient; the proportion of HSCs in human peripheral blood is too low (less than 0.1%), and granulocyte colony-stimulating factor ( G-CSF) mobilizes hematopoietic stem cells to migrate from bone marrow to peripheral blood.
- G-CSF granulocyte colony-stimulating factor
- the mobilization effect is often poor, the number of HSCs contained is insufficient, and repeated mobilization or transplantation fails.
- HSCs derived from bone marrow and mobilized peripheral blood all require human leukocyte antigen (HLA) matching between donors and patients. HLA matching is difficult. Once mismatch occurs, graft-versus-host reaction (GVHD) will occur, and a large number of patients with GVHD will die from immune system disorders. HSCs derived from umbilical cord blood have low requirements for the degree of HLA matching, allowing partial HLA mismatch, and the incidence of GVHD after transplantation is low, which alleviates the difficulty of traditional HSCT matching.
- HLA human leukocyte antigen
- GVHD graft-versus-host reaction
- HSCs derived from umbilical cord blood have low requirements for the degree of HLA matching, allowing partial HLA mismatch, and the incidence of GVHD after transplantation is low, which alleviates the difficulty of traditional HSCT matching.
- the common problem faced by the HSCs collected by the above three methods is the small amount of cells, which sometimes can only meet the transplantation needs of children or light-weight adults
- one of the ideas for culturing hematopoietic stem cells in vitro is to add small molecule compounds to the medium to target and regulate the division and proliferation signals of hematopoietic stem cells, so that hematopoietic stem cells can maintain a certain degree of expansion by changing the state of cell division and proliferation. , and maintain its self-renewal capacity.
- platelet-derived growth factor PDGF platelet-derived growth factor
- platelet-derived growth factor receptor PDGFR platelet-derived growth factor receptor
- PDGF is a pro-angiogenic factor isolated from human platelets
- PDGFR is a member of the tyrosine protein kinase family located on the cell membrane.
- PDGF must bind to PDGFR, activate PDGFR by phosphorylation, and activate the PDGF/PDGFR signaling pathway in order to exert biological effects. For example, it can stimulate fibroblasts, glial cells, smooth muscle cells, etc. The cells enter the division and proliferation cycle.
- the PDGF/PDGFR signaling pathway has been widely reported in many types of cells, but less reported in hematopoietic stem cells.
- the role of PDGF/PDGFR signaling pathway in hematopoietic stem cell expansion and maintenance of self-renewal capacity is still a research gap.
- the present invention provides a medium composition, a cell population and its application for expanding and maintaining the self-renewal ability and differentiation potential of HSCs.
- the inventors of the present invention continuously add PDGFR inhibitors when culturing HSCs from different sources in vitro, which can maintain the expansion of HSCs to a certain extent, but at the same time maintain the self-renewal ability of a high proportion of HSCs, so that in the cell culture product, A large number of LT-HSCs with transplantation potential can be obtained, and the effect is better than that of chemical small molecules known to culture HSCs. This is the first report in the study of hematopoietic stem cell expansion and self-renewal capacity.
- a medium composition for expanding and maintaining hematopoietic stem cells comprising hematopoietic stem cell culture medium and a small molecule inhibitor of PDGFR target.
- composition according to item 1 wherein the small molecule inhibitor of the PDGFR target is selected from one or more of the following: AG1296, PDGFR inhibitor 1, Imatinib, PP121, Ponatinib, Axitinib, Trapidil and Erdafitinib, preferably AG1296.
- the medium composition according to item 1 or 2, wherein the hematopoietic stem cell medium comprises: 1) a basal medium (preferably a serum-free basal medium); 2) a growth factor; and/or 3) cytokines.
- the concentration of the growth factor Flt-3L is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor SCF is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor TPO is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the interleukin IL-6 is 1-50ng/ml, preferably 1-20ng/ml.
- HSCs are derived from bone marrow, mobilized peripheral blood, umbilical cord blood, cryopreserved and resuscitated HSCs or HSCs transformed by gene editing.
- a method for promoting the expansion of HSCs and maintaining the self-renewal capacity of the HSCs comprising in vitro culturing the HSCs in a medium composition containing a small molecule inhibitor of a PDGFR target.
- the small molecule inhibitor of the PDGFR target is selected from one or more of the following: AG1296, PDGFR inhibitor 1, Imatinib, PP121, Ponatinib, Axitinib, Trapidil and Erdafitinib, preferably AG1296.
- the hematopoietic stem cell culture medium comprises: 1) a basal medium (preferably a serum-free basal medium); 2) growth factors; and/or 3) cytokines.
- the growth factor or cytokine is selected from one or more of the following: Flt-3L, growth factor SCF, growth factor TPO and interleukin IL-6.
- the concentration of the growth factor Flt-3L is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor SCF is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor TPO is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the interleukin IL-6 is 1-50ng/ml, preferably 1-20ng/ml.
- concentration of the small molecule inhibitor of the PDGFR target in the medium composition is 0.1-100 ⁇ M, preferably 0.5-50 ⁇ M, more preferably 1-10 ⁇ M.
- HSCs are derived from bone marrow, mobilized peripheral blood, umbilical cord blood, cryopreserved resuscitated HSCs or genetically modified HSCs.
- in vitro culture time is about 4-21 days, preferably about 6-15 days, more preferably about 6-10 days, most preferably about 6 days -8 days.
- An HSCs infusion solution wherein the ratio of the number of CD34+ phenotype HSCs cells to the total number of cells is 40-85%, preferably 60-85%, more preferably 75-80%.
- HSCs infusion solution according to item 20 wherein the number of CD34+CD90+ phenotype HSCs cells accounts for 6-15% of the total cells, preferably 8-15%, more preferably 8-12% .
- HSCs infusion solution according to any one of items 20-22, wherein the cells of CD34+CD45+CD90+CD45RA-CD38- phenotype of HSCs account for 2-5% of the total cells, preferably 2.5-4%.
- a method of replenishing blood cells to an individual in need thereof comprising infusing the HSCs infusion solution of any one of items 20-24 to the individual.
- the small molecule inhibitor of PDGFR target is selected from one or more of the following: AG1296, PDGFR inhibitor 1, Imatinib, PP121, Ponatinib, Axitinib, Trapidil and Erdafitinib, preferably AG1296.
- a method of preventing or treating a disease in an individual comprising infusing the HSCs infusion solution of any one of items 20-24 to the individual.
- the applicant's findings demonstrate for the first time that inhibitors of PDGFR can significantly expand HSCs during in vitro culture, while maintaining a high proportion of HSCs' self-renewal capacity.
- the PDGFR inhibitor discovered by Applicants is significantly more effective than the reported small chemical molecules in amplifying LT-HSCs. This is the first time to demonstrate and report that the PDGF/PDGFR signaling pathway plays an important role in the expansion of hematopoietic stem cells and the maintenance of self-renewal capacity.
- the applicant's research results can realize the in vitro expansion of HSCs while maintaining a relatively high proportion of stemness. On this basis, the clinical application of HSCs transplantation can widely treat a series of hematological diseases.
- Figure 1 shows the determination of the logic gate and gate position of the target cell population CD34+CD45+CD45RA-CD90+CD38- cell population.
- Figure 2 shows the optimal concentration of compounds and screening for maintaining the stemness of HSCs on cord blood-derived CD34+ cells.
- the compounds in Table 1 (3 test concentrations of each compound) were induced for 6-8 days after induction.
- Flow cytometry LT- The expression analysis chart of HSCs cell surface markers (CD34+CD45+CD90+CD45RA-CD38-), the abscissa represents the name of the inhibitor and the concentration used, and the ordinate represents the expansion fold of the ratio of LT-HSCs in the experimental group/control group.
- Figure 33A shows the screening of the optimal concentration of compound AG1296 to maintain the stemness of HSCs on umbilical cord blood-derived CD34+ cells, and the cell surface markers of LT-HSCs (CD34+CD45+CD90+CD45RA- CD38-) expression analysis diagram, the abscissa represents the name of the inhibitor and the concentration used, the ordinate is CD34+(%), CD34+CD90+(%), CD34+CD90+CD45RA-(%), CD34+CD45+CD90+CD45RA- CD38-(%) represents the proportion of cells expressing different markers in total cells.
- 3B shows the optimal concentration screening of small molecule compound AG1296 to expand HSCs on cord blood-derived CD34+ cells, the total cell number was counted 6 days after compound induction treatment, and the cell surface markers (CD34+CD45+CD90) were detected by flow cytometry.
- Figure 4 4A shows the screening of the optimal concentration of compound AG1296 to maintain the stemness of HSCs on umbilical cord blood-derived CD34+ cells, and the cell surface markers of LT-HSCs (CD34+CD45+CD90+CD45RA- CD38-) expression analysis diagram
- the abscissa represents the name of the inhibitor and the concentration used
- the ordinate is CD34+(%), CD34+CD90+(%), CD34+CD90+CD45RA-(%), CD34+CD45+CD90+CD45RA- CD38-(%) represents the proportion of cells expressing different markers in total cells.
- 4B shows the optimal concentration screening of the small molecule compound AG1296 to expand HSCs on cord blood-derived CD34+ cells, the total cell number was counted 6 days after compound induction treatment, and the cell surface markers (CD34+CD45+CD90) were detected by flow cytometry.
- Figure 55A shows the comparison of compound AG1296 with known literature-reported inhibitors SR1 and UM171 in maintaining stemness of HSCs on mobilized peripheral blood-derived CD34+ cells.
- FIG. 5B shows a comparison of the cell expansion of compound AG1296 with known literature-reported inhibitors SR1 and UM171 on mobilized peripheral blood-derived CD34+ cells.
- Figure 6 shows a graph of the analysis of in vitro clonogenic ability of AG1296 at various concentrations on cord blood-derived CD34+ cells.
- BFU-E, CFU-E, CFU-GM, CFU-GEMM represent clones of different blood lineages such as erythroid, myeloid, and lymphoid.
- the abscissa represents the name of the inhibitor and the concentration used
- the number of clones on the ordinate represents the total number of clones
- the number of GEMM clones represents the number of CFU-GEMM clones.
- Figure 7 shows the determination of logic gates and gate positions for the hCD45+, hCD19+, hCD33+, hCD3+ and hCD56+ cell populations of interest.
- Figure 8 8A shows the comparison of the effect of compound AG1296 and the known inhibitor SR1 reported in the literature, in vitro culture and mobilization of peripheral blood-derived CD34+ cells and in vivo transplantation in immunodeficient mice.
- the CD34+ cells derived from peripheral blood were mobilized and cultured with small molecule inhibitors in vitro for 6 days.
- Immunodeficiency mice were transplanted.
- the proportion of human CD45+ cells in the bone marrow cells of the mice was detected 18 weeks after transplantation.
- the abscissa represents the name of the inhibitor, and the ordinate represents the proportion of human CD45+ cells in the mouse bone marrow cells.
- FIG. 8B shows the comparison of the ability of compound AG1296 to form cells of each lineage after in vitro mobilization of peripheral blood-derived CD34+ cells and in vivo transplantation of immunodeficient mice with the known inhibitor SR1 reported in the literature.
- the CD34+ cells derived from peripheral blood were mobilized and cultured with small molecule inhibitors in vitro for 6 days, and then immunodeficient mice were transplanted.
- the abscissa represents the name of the inhibitor, and the ordinate represents the proportion of human lineage cells in mouse bone marrow cells.
- the present invention provides a medium composition for expanding and maintaining the self-renewal ability and differentiation potential of HSCs, which comprises a small molecule inhibitor of PDGFR target.
- the self-renewal ability of HSCs refers to the ability to generate stem-like HSCs without differentiation.
- the small molecule inhibitor refers to a molecular entity (usually organic or organometallic) that is not a polymer, is pharmaceutically active, and has less than about 2 kDa, less than about 1 kDa, less than about 900 Da, less than about 800 Da, or With molecular weights less than about 700 Da, small molecule inhibitors can be synthetic, semi-synthetic (ie, synthesized from naturally occurring precursors) or biologically obtained.
- the small molecule inhibitor of the PDGFR target is selected from one or more of the following: AG1296, PDGFR inhibitor 1, Imatinib, PP121, Ponatinib, Axitinib, Trapidil and Erdafitinib; preferably AG1296.
- the AG1296 is a synthetic quinoline compound, which is an enzyme inhibitor, which can competitively inhibit PDFGR with ATP.
- the PDGFR inhibitor 1 is a synthetic enzyme inhibitor, which can inhibit the PDGFR target.
- the Imatinib is a synthetic multi-target tyrosine kinase inhibitor, which can inhibit the PDGFR target.
- the PP121 is a synthetic multi-target inhibitor, which can inhibit the PDGFR target.
- the Ponatinib is a synthetic multi-target inhibitor, which can inhibit the PDGFR target.
- the Axitinib is a synthetic multi-target inhibitor, which can inhibit the PDGFR target.
- the Trapidil is a synthetic PDGF antagonist that can disrupt the autocrine loops of PDGF and PDGFR.
- the Erdafitinib is a synthetic FGFR inhibitor that can also inhibit PDGFR targets.
- the composition further comprises a hematopoietic stem cell culture medium
- the hematopoietic stem cell culture medium comprises: 1) a basal medium (preferably a serum-free basal medium) 2) growth factors; and/or 3) cytokines;
- the growth factor or cytokine is selected from one or more of the following: growth factor Flt-3L, growth factor SCF, growth factor TPO and interleukin IL-6;
- the concentration of the growth factor Flt-3L is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor SCF is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor TPO is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the interleukin IL-6 is 1-50ng/ml, preferably 1-20ng/ml.
- Described basal medium refers to can provide basal nutrient material required for cell proliferation, all basal medium contains substances such as amino acids, vitamins, carbohydrates, inorganic ions, and described basal medium can be self-made (i.e. It is necessary to use powder to make liquid by itself), or it can be commercially available (ie, liquid).
- the basal medium includes serum-containing basal medium and serum-free basal medium.
- the serum in the described serum-containing basal medium can be fetal bovine serum or calf serum, etc.;
- Described serum-free basal medium can be, for example, SFEM, SFEM II, H3000, StemSpan TM ACF; StemPro-34 from ThermoFisher; Stemline II from Sigma; StemXVivo from R&D; X-VIVO 15 from Lonza; SCGM from CellGenix, etc.
- the growth factor Flt-3L refers to human FMS-related tyrosine kinase 3 ligand, which can stimulate the proliferation of hematopoietic stem cells.
- the growth factor SCF refers to human stem cell factor, which can stimulate the proliferation of hematopoietic stem cells.
- the growth factor TPO refers to human thrombopoietin, which can stimulate the proliferation of hematopoietic stemness.
- the interleukin IL-6 refers to human interleukin-6, which can promote the proliferation of hematopoietic stem cells.
- the SFEM II medium refers to a serum-free basal medium for culturing hematopoietic stem cells from StemCell, which is suitable for culturing hematopoietic stem cells.
- the concentration of the growth factor Flt-3L can be 10ng/ml, 20ng/ml, 30ng/ml, 40ng/ml, 50ng/ml, 60ng/ml, 70ng/ml, 80ng/ml, 90ng/ml, 100ng /ml, 110ng/ml, etc.;
- the concentration of the growth factor SCF can be 10ng/ml, 20ng/ml, 30ng/ml, 40ng/ml, 50ng/ml, 60ng/ml, 70ng/ml, 80ng/ml, 90ng/ml, 100ng/ml, 110ng /ml, etc.;
- the concentration of the growth factor TPO can be 10ng/ml, 20ng/ml, 30ng/ml, 40ng/ml, 50ng/ml, 60ng/ml, 70ng/ml, 80ng/ml, 90ng/ml, 100ng/ml, 110ng /ml, etc.;
- the concentration of the interleukin IL-6 can be 1 ng/ml, 5 ng/ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, 40 ng/ml, 50 ng/ml and the like.
- the hematopoietic stem cell culture medium includes, for example, serum-free basal culture, growth factor Flt-3L, growth factor SCF, growth factor TPO and interleukin IL-6 or the hematopoietic Stem cell culture medium may include serum-free basal medium, growth factor Flt-3L, growth factor SCF, and growth factor TPO.
- the hematopoietic stem cell medium refers to a medium for culturing hematopoietic stem cells.
- the concentration of the small molecule inhibitor of PDGFR target in the medium composition is 0.1-100 ⁇ M, preferably 0.5-50 ⁇ M, more preferably 1- 10 ⁇ M.
- the concentration of the small molecule inhibitor of the PDGFR target in the medium composition may be 0.1 ⁇ M, 0.5 ⁇ M, 1 ⁇ M, 2 ⁇ M, 3 ⁇ M, 4 ⁇ M, 5 ⁇ M, 6 ⁇ M, 7 ⁇ M, 8 ⁇ M, 9 ⁇ M, 10 ⁇ M, 15 ⁇ M, 20 ⁇ M, 30 ⁇ M, 40 ⁇ M, 50 ⁇ M, 60 ⁇ M, 70 ⁇ M, 80 ⁇ M, 90 ⁇ M, 100 ⁇ M, etc.
- the HSCs are derived from bone marrow, mobilized peripheral blood, umbilical cord blood, cryopreserved and resuscitated HSCs or HSCs transformed by gene editing.
- the present invention provides an HSCs infusion solution, wherein the number of CD34+ phenotype HSCs cells accounts for 40-85% of all cells, preferably 60-85%, and more preferably 75-80%.
- the proportion of CD34+ phenotype HSCs in the total cells can be 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, etc.
- the whole cell refers to all progeny cells after the initial CD34+ cells have been cultured.
- the number of HSCs with CD34+CD90+ phenotype accounts for 6-15% of all cells, preferably 8-15%, more preferably 8-12%.
- the proportion of CD34+CD90+ phenotype HSCs in the total cells can be 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, etc.
- the number of HSCs with CD34+CD90+CD45RA- phenotype accounts for 2-10% of all cells, preferably 2-6%, more preferably 4- 5%.
- the proportion of CD34+CD90+CD45RA- phenotype HSCs in the total cells can be 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, etc.
- the number of cells of HSCs with CD34+CD45+CD90+CD45RA-CD38- phenotype accounts for 2-5% of all cells, preferably 2.5-4%.
- the number of cells in HSCs of CD34+CD45+CD90+CD45RA-CD38- phenotype can be 2%, 3%, 4%, 5%, etc. in the total cells.
- the HSCs are derived from bone marrow, mobilized peripheral blood, umbilical cord blood, cryopreserved and resuscitated HSCs or HSCs transformed by gene editing.
- the present invention provides a method for replenishing blood cells to an individual in need, comprising infusion of the above-mentioned HSCs infusion solution to the individual.
- the colonization and differentiation of the HSCs in the individual is detected after the infusion of the HSCs infusion solution into the individual.
- the HSCs colonize and differentiate into blood cells in the individual.
- whether the HSCs can colonize and differentiate in the individual can be detected by a conventional method in the art for detecting the colonization and differentiation of HSCs. For example, after mobilizing peripheral blood hematopoietic stem cells for transplantation, there will be two peaks in the increase of neutrophils.
- the first peak is about 11 days after transplantation on average, and peripheral blood neutrophils reach 0.5 ⁇ 10 9 /L, and then the There was a downward trend, and the second peak appeared again 3 to 4 weeks after transplantation, and then returned to normal. Therefore, whether HSCs successfully colonized and differentiated after HSCs infusion can be judged by detecting the number of neutrophils in peripheral blood.
- the number of platelets in peripheral blood can also be detected to determine whether HSCs are successfully colonized and differentiated after HSCs infusion. For example, the average time after the infusion is about 13 days to detect whether the peripheral blood platelets reach 50 ⁇ 10 9 /L.
- peripheral blood neutrophils After umbilical cord blood hematopoietic stem cell transplantation, determine whether peripheral blood neutrophils reach 5 ⁇ 10 9 /L in an average of 22 to 24 days; or detect whether peripheral blood platelets reach 5 ⁇ 10 in an average of 48 to 54 days 9 /L.
- the peripheral blood of the individual is continuously monitored, and the absolute neutrophil count is greater than or equal to 0.5 ⁇ 10 9 /L for 3 consecutive days; or the platelet count is greater than 20 ⁇ 10 9 /L.
- there are some indicators, such as sex chromosome change, blood type change, short tandem repeat (short tandem repeat, STR) to the donor type can also be used as a marker of successful implantation.
- the present invention provides a method for promoting the expansion of HSCs and maintaining the self-renewal capacity of HSCs, comprising in vitro culturing HSCs in a medium composition containing a small molecule inhibitor of PDGFR target.
- the invention can promote the expansion of HSCs and maintain the self-renewal ability of HSCs by culturing HSCs in vitro with the medium composition containing the small molecule inhibitor of PDGFR target. Differentiate into cells of different lineages.
- the small molecule inhibitor of the PDGFR target is selected from one or more of the following: AG1296, PDGFR inhibitor 1, Imatinib, PP121, Ponatinib, Axitinib, Trapidil and Erdafitinib; preferably AG1296.
- the medium composition comprises a hematopoietic stem cell medium
- the hematopoietic stem cell medium comprises 1) a basal medium (preferably a serum-free basal medium) 2) growth factors; and/or 3) cytokines.
- the growth factor or cytokine is selected from one or more of the following: Flt-3L, growth factor SCF, growth factor TPO and interleukin IL-6;
- the concentration of the growth factor Flt-3L is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor SCF is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor TPO is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the interleukin IL-6 is 1-50ng/ml, preferably 1-20ng/ml.
- the concentration of the small molecule inhibitor of the PDGFR target in the medium composition is 0.1-100 ⁇ M, preferably 0.5-50 ⁇ M, more preferably 1- 10 ⁇ M.
- the in vitro contact time is about 4-21 days, preferably about 6-15 days, more preferably about 6-10 days, and most preferably about 6-8 days .
- the period of in vitro exposure can be about 4-21 days, about 4-20 days, about 4-19 days, about 4-18 days, about 5-21 days, about 5-20 days, about 5-19 days, about 5-18 days, about 6-18 days, about 6-17 days, about 6-16 days, about 6-15 days, about 6-14 days, about 6-13 days, about 6-12 days, about 6 -11 days, about 6-10 days, about 6-9 days, about 6-8 days, etc.
- the number of HSCs with CD34+ phenotype accounts for 40-85% of the total cells, preferably 60-85%, and more preferably 75%. -80%.
- the number of HSCs with CD34+CD90+ phenotype accounts for 6-15% of all cells, preferably 8-15%, and more preferably 8-12%.
- the number of HSCs with CD34+CD90+CD45RA- phenotype accounts for 2-10% of the total cells, preferably 2-6% , more preferably 4-5%.
- the number of HSCs with CD34+CD45+CD90+CD45RA-CD38- phenotype accounts for 2-5% of all cells, preferably 2.5-4%.
- the HSCs are derived from bone marrow, mobilized peripheral blood, umbilical cord blood, cryopreserved and resuscitated HSCs or HSCs transformed by gene editing.
- the present invention uses a small molecule inhibitor of PDGFR target to expand HSCs cells in vitro, and can expand cells from different sources, such as the above-mentioned HSCs cells derived from bone marrow, mobilized peripheral blood or umbilical cord blood, and cryopreserved and resuscitated HSCs or Gene-edited HSCs.
- the present invention provides a cell population, wherein the proportion of CD34+ cells in the cell population is 40-85%.
- the cell population refers to the in vitro cell product, which refers to the cell population obtained by contacting HSCs with a medium composition containing a small molecule inhibitor of PDGFR target in vitro.
- the proportion of CD34+ cells in the cell population is 60-85%, preferably 75-80%.
- the cell population is obtained by culturing HSCs in vitro in a medium composition containing a small molecule inhibitor of PDGFR target.
- the cell population is capable of maintaining stemness and, after implantation, can differentiate into cells of different lineages for the treatment of different diseases.
- the small molecule inhibitor of the PDGFR target is selected from one or more of the following: AG1296, PDGFR inhibitor 1, Imatinib, PP121, Ponatinib, Axitinib, Trapidil and Erdafitinib; preferably AG1296.
- the medium composition comprises a hematopoietic stem cell medium
- the hematopoietic stem cell medium comprises: 1) a basal medium (preferably a serum-free basal medium ); 2) growth factors; and/or 3) cytokines;
- the growth factor or cytokine is selected from one or more of the following: Flt-3L, growth factor SCF, growth factor TPO and interleukin IL-6;
- the concentration of the growth factor Flt-3L is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor SCF is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the growth factor TPO is 10-110ng/ml, preferably 50-100ng/ml;
- the concentration of the interleukin IL-6 is 1-50ng/ml, preferably 1-20ng/ml.
- the concentration of the small molecule inhibitor of PDGFR target in the medium composition is 0.1-100 ⁇ M, preferably 0.5-50 ⁇ M, more preferably 1- 10 ⁇ M.
- the HSCs are derived from bone marrow, mobilized peripheral blood, umbilical cord blood, cryopreserved and resuscitated HSCs or HSCs transformed by gene editing.
- the cell population differentiates into blood cells of different lineages after implantation in vivo.
- it can differentiate into B cells, T cells, NK cells, dendritic cells, granulocytes, macrophages, megakaryocytes or erythrocytes.
- the present invention provides a method for preventing or treating a disease of an individual, comprising infusion of the above-mentioned HSCs infusion solution or the above-mentioned cell population to the individual.
- the present invention provides the use of a small molecule inhibitor of PDGFR target in promoting the expansion of HSCs and maintaining the self-renewal ability of HSCs, preferably, the small molecule inhibitor of PDGFR target is selected from one or more of the following Species: AG1296, PDGFR inhibitor 1, Imatinib, PP121, Ponatinib, Axitinib, Trapidil, and Erdafitinib; preferably AG1296.
- the HSCs are derived from bone marrow, mobilized peripheral blood, umbilical cord blood, cryopreserved and resuscitated HSCs or HSCs transformed by gene editing.
- the present invention provides the use of the above-mentioned HSCs infusion solution or the above-mentioned cell population in preparing a medicine for preventing or treating diseases.
- the disease is a disease requiring replenishment of blood cells.
- the blood cells when the blood cells are red blood cells, anemia and the like can be treated;
- the blood cells when the blood cells are leukocytes, it can treat leukopenia, agranulocytosis, eosinophilia, acute leukemia, chronic leukemia, myelodysplastic syndrome, Malignant lymphoma (Hodgkin's lymphoma, non-Hodgkin's lymphoma), infectious mononucleosis, malignant histiocytosis, multiple myeloma, etc.;
- aplastic anemia, acute leukemia, acute radiation sickness, etc. can be treated;
- the PDGFR inhibitor of the present invention can significantly expand HSCs during in vitro culture, while maintaining a high proportion of the self-renewal capacity of HSCs.
- the PDGFR inhibitor can amplify cells from different sources in vitro, and after the amplified cells are implanted into the body, they can differentiate into cells of different lineages, and can widely treat a series of blood system diseases.
- LT -HSCs is the abbreviation of Long Term Hemopoietic Stem Cells, which refers to a class of stem cells with high differentiation potential that are in a quiescent state and capable of self-renewal, and can support the reconstruction of the long-term hematopoietic system. Reconstruction of recipient hematopoietic system in secondary transplantation.
- HSCs hematopoietic stem cells
- stemness The self-renewal ability and differentiation potential of hematopoietic stem cells.
- LT-HSCs are the most self-renewing and differentiation potential group of hematopoietic stem cells, and can support the reconstruction of the long-term hematopoietic system.
- the present invention generally and/or specifically describes the materials and test methods used in the test.
- % in the chemical materials used means wt%, that is, weight percentage .
- the reagents or instruments used without the manufacturer's indication are all conventional reagent products that can be obtained from the market.
- the amount of reagent is determined according to the cell count result) to resuspend the cells, then add pre-mixed CD34 MicroBeads (CD34 MicroBead Kit UltraPure, human: MiltenyiBiotec, product number: 130-100-453), mix well, 4 Incubate in the refrigerator for 30 min. Add physiological saline (1% HSA) to the centrifuge tube to a final volume of 50 ml, transfer to a high-speed centrifuge, and centrifuge at 500 g for 10 min.
- CD34 MicroBeads CD34 MicroBead Kit UltraPure, human: MiltenyiBiotec, product number: 130-100-453
- the MS Column or LS Column was washed with 1 ml (MS column) or 3 ml (LS column) saline (1% HSA). Repeat 3 times. Transfer the sorting column to the top of a new 15ml centrifuge tube, add 2ml (MS column) or 3ml (LS column) physiological saline (1%HSA) to elute the target cells, and then add 1ml (MS column) or 2ml (LS column) The target cells were repeatedly eluted with physiological saline (1% HSA). Take 20 ⁇ L of cell suspension to count in a cell counter (Nexcelom, model: Cellometer K2), and centrifuge the remaining cell suspension at 400 g for 5 min.
- a cell counter Neexcelom, model: Cellometer K2
- the preparation of the small molecule inhibitor stock solution is carried out. Then proceed to the preparation of hematopoietic stem cell culture medium: SFEM II medium (stem cell, article number: 09655) + 50ng/ml growth factor Flt-3L (PeProtech, article number: 300-100UG) + 50ng/ml growth factor SCF (PeProtech, article number) : 300-07-100UG)+50ng/ml growth factor TPO (PeProtech, item number: 300-18-100UG)+10ng/ml interleukin IL-6 (PeProtech, item number: 200-06-20UG)+1% double Antibody (HyClone, Cat. No. sv30010). According to the set concentration gradient of the small molecule inhibitor, use the stock solution and the basal medium to prepare the medium containing different concentrations of the small molecule inhibitor.
- the final volume of the cell culture solution per well is 1ml
- the total number of cells per well is 2*10 ⁇ 5 cells calculated according to the cell density per well
- the density of 50 ⁇ l of cell suspension added to each well is 4*10 ⁇ 6/ml , adjust the density of the spare HSCs in Example 1 to the calculated density of the cell suspension, and add it; take out the preheated medium from the incubator, add 50 ⁇ l of the cell suspension to each well, and after mixing, the microscope (OLYMPUS, model: CKX53) to observe the cell state, and then put it into an incubator for culture.
- Antibody name factory article number APC/Cy7 anti-human CD45 Biolegend 304014 APC anti-human CD38 Biolegend 356606 Brilliant Violet 510™ anti-human CD34 Biolegend 343528 PE anti-human CD90(Thy1) Biolegend 328110 FITC anti-human CD45RA Biolegend 304106 APC Mouse IgG2a, ⁇ Isotype Ctrl Biolegend 400220 APC/Cyanine7Mouse IgG1, ⁇ Isotype Ctrl Biolegend 400128 PE Mouse IgG2a, ⁇ Isotype Ctrl Biolegend 400212 FITC Mouse IgG2b, ⁇ Isotype Ctrl Biolegend 402208
- PBS phosphate-buffered saline, HyClone, product number: SH30256.01
- HSA human serum albumin, Guangdong Shuanglin, catalog number: S10970069
- the controls were set as the NC group and the ISO group respectively, and the cells were selected from any sample or mixed cells of the samples to be tested in this batch of experiments, depending on the number of cells. In the same batch of experiments, each control group did not have repeated detection. See Table 3 for group settings.
- the test results are analyzed as follows: 1) The target cell population is CD34+CD45+CD45RA-CD90+CD38- cell population; 2) The determination of the logic gate and gate position is shown in Figure 1: first delineate the cell population, P1 gate; source The cell population from the P1 gate removes adherent cells, and it is the P2 gate; the cell population from the P2 gate is delineated by NC or ISO to delineate the CD34, CD45, CD45RA negative cell population, which is the Q3-LL gate (CD34-CD45-), Q5-UL +Q5-LL gate (CD45RA-); FMO90 delineates the CD90-negative cell population, which is the Q5-LL+Q5-LR gate; FMO38 delimits the CD38-negative cell population, which is the Q6-LR gate; the gate delineated by NC, ISO, FMO , confirm that the cells delineated by the Q3-UR-Q5-UL-Q6-LR gate are CD34+CD45+CD45RA-CD90
- Example 3 On the umbilical cord blood-derived CD34+ cells sorted in Example 1, the optimal concentration of small molecule inhibitors and the screening of the ability to maintain the stemness of HSCs were carried out in the same way as in Example 2. After 6-8 days of small molecule induction, The expression of LT-HSCs cell surface markers (CD34+CD45+CD90+CD45RA-CD38-) was detected by flow cytometry in the same way as in Example 3.
- Example 3 On the umbilical cord blood-derived CD34+ cells sorted in Example 1, the screening inhibitor AG1296 was screened for the optimal concentration in the same way as in Example 2. After 6 days of induction with different concentrations of the small molecule inhibitor AG1296, the expression of LT-HSCs cell surface markers (CD34+CD45+CD90+CD45RA-CD38-) was detected by flow cytometry using the same method as in Example 3.
- AG1296 was better at concentrations of 1 ⁇ M, 5 ⁇ M and 10 ⁇ M in maintaining the stemness and absolute cell number of LT-HSCs on umbilical cord blood-derived HSCs.
- Example 2 On the mobilized peripheral blood-derived CD34+ cells sorted in Example 1, the screened inhibitor AG1296 and literature (Fares I, et al. Science. 2014; Boitano AE, et al were tested in the same way as in Example 2). .Science.2010;) reported inhibitors UM171, SR1 for comparison. Eight days after the induction of the small molecule inhibitor, the expression of LT-HSCs cell surface markers (CD34+CD45+CD90+CD45RA-CD38-) was detected by flow cytometry in the same way as in Example 3.
- Example 7 CD34+ hematopoietic stem cell colony formation culture
- CFU colony-forming unit
- Carry out cell inoculation count the cells in suspension after 7 days of expansion and culture after induction with small molecule inhibitors (cord blood-derived CD34+ hematopoietic stem cells induced by small molecule inhibitors), and draw cells with 100 times the inoculation density according to the counting results.
- Suspension for example, if the seeding density is 100cells/well/3ml, 10000cells should be collected, add to 1ml of 2% FBS (Gibco, Cat. No. 16000-044)-IMDM (Gibco, Cat. No.: 12440-053) medium, mix Even spare.
- 3cc Syringes (Stem cell, Item No.: 28240) is used in conjunction with Blunt-End Needles 16Gauge (Stemcell, Item No.: 28110), aspirate the obtained cell suspension to 1 mL, push it out of the syringe to exhaust the gas in the syringe, and re-absorb all the obtained cell suspension.
- 3 mL of SmsrtDishTM-6 (stem cell, product number: 27370, 6-well plate) was injected into one well, and the 6-well plate was slowly tilted so that the cell suspension evenly covered the bottom of the well.
- CFU-GEMM (CFU-G, CFU-E, CFU-MM): granulocyte-erythrocyte-macrophage-megakaryocyte colony forming unit.
- a colony contains erythrocytes and 20 or more non-erythrocytes (granulocytes, macrophages, and/or megakaryocytes), usually with erythrocytes in the center of the colony, surrounded by non-erythrocytes, and non-erythrocytes can also be concentrated on one side of the erythrocytes.
- Colonies of CFU-GEMM were generally larger than those of CFU-GM or BFU-E. Rare in most cell samples (usually 10% of total colonies).
- CFU-GM Colonies containing more than 20 granulocytes (CFU-G) and/or macrophages (CFU-M). Without appearing red or brown, individual cells within colonies are often distinguishable, especially at the colony edges, and large colonies may have one or more dense dark nuclei. Erythropoietin (EPO) is not required for colony growth and differentiation.
- CFU-G granulocytes
- CFU-M macrophages
- BFU-E Burst erythrocyte colony-forming unit, forming colonies of single or multiple cell clusters, each colony containing >200 mature erythrocytes. When cells are hemoglobinated they appear red or brown, making it difficult to distinguish individual cells within each cluster, BFU-E are more immature progenitor cells that require erythropoietin (EPO) and other cytokines, especially interleukin 3, for their growth (IL-3) and stem cell factor (SCF) to promote optimal growth of their colonies.
- EPO erythropoietin
- IL-3 interleukin 3
- SCF stem cell factor
- CFU-E erythrocyte colony-forming unit, can form 1-2 cell clusters containing 8-200 red blood cells, when the cells are hemoglobinized, they appear red or brown, and it is difficult to distinguish individual cells within the colony.
- CFU-E are progenitors of the mature erythroid lineage and require erythropoietin (EPO) to promote their differentiation.
- Example 7 The comparison of the in vitro clonogenic ability of the screened PDGFR inhibitor AG1296 at different concentrations was performed on the umbilical cord blood-derived CD34+ cells sorted in Example 1. Cells were treated with different concentrations of AG1296, and after 8 days, in vitro clone (CFU) formation detection was carried out in the same way as in Example 7, the number of clones was counted 14 days after inoculation of cells, and CFU-GEMM was analyzed. The results are shown in Figure 6 , among which, BFU-E, CFU-E, CFU-GM, CFU-GEMM represent clones of different blood lineages such as erythroid, myeloid, and lymphoid.
- CFU in vitro clone
- Example 9 Comparison of the effects of the screened PDGFR inhibitor AG1296 and the inhibitor SR1 reported in the literature on hematopoietic stem cell transplantation in vivo
- Example 2 On the umbilical cord blood-derived CD34+ cells sorted in Example 1, the screened small molecule inhibitor AG1296 was compared with the in vivo hematopoietic system reconstitution ability of the inhibitor SR1 reported in the literature.
- the concentrations and groups of small molecule inhibitors used in this example are shown in Table 4.
- LT-HSCs cell surface markers CD34+CD45+CD90+CD45RA-CD38-
- mice were prepared, with 8 mice per group. Mice were purchased from Beijing Weitongda Biotechnology Co., Ltd., the strain was NPG (NOD-Prkdc scid ll2rg null /Vst), 6-week-old female mice, and the weight difference between mice was controlled within 3 g. The mice were irradiated with a half-lethal dose before cell transplantation, and the irradiation dose was 1.6 Gy.
- NPG NOD-Prkdc scid ll2rg null /Vst
- the cultured cell suspension (the initial culture cell amount is 0.28*10 ⁇ 5/ml/well), centrifuge at room temperature, centrifuge at 400g for 5min, discard the supernatant, and resuspend the cell pellet with 100 ⁇ l of normal saline (containing 1% HSA). Then, an irradiated NPG mouse was injected into the tail vein, and the mice in different groups were marked.
- mice After the cells were transplanted into the mice, the mice were sacrificed at the 18th week, and the bone marrow cells of the mice were collected, and the proportions of human CD45, human CD19, human CD3, human CD33 and human CD56 were detected by flow cytometry.
- Antibodies, 7-AAD dyes and sources used in this example are shown in Table 5.
- Antibody name factory article number FITC anti-mouse CD45 Biolegend 103108 APC/Cy7 anti-human CD45 Biolegend 304014 Brilliant Violet 510 TM anti-human CD3 Biolegend 300448 PE anti-human CD19 Biolegend 363004 Brilliant Violet 421 TM anti-human CD33 Biolegend 303416 APC anti-human CD56 Biolegend 304610 7-AAD Viability Staining Solution Biolegend 420404
- mice were sacrificed by cervical dislocation, and the tibia and femur of one hind leg of the mice were taken.
- a 1 ml syringe was used to draw pre-cooled PBS (containing 1% HSA), the needle was inserted into one end of the bone marrow cavity, and the PBS was injected forcefully to flush out the bone marrow cells from the other end of the bone marrow cavity.
- Tibial and femoral marrow cavities were rinsed with 2 ml of PBS, respectively.
- the bone marrow cell suspension was repeatedly sucked with a pipette, filtered with a 40um cell mesh (BD, catalog number: 352340), and centrifuged at room temperature, 400g, 5min. After centrifugation, the supernatant was discarded, and the bone marrow cells were used for later use.
- BD 40um cell mesh
- the test results were analyzed as follows: 1) The target cell population was human CD45+ cell population, human CD19+ cell population, human CD3+ cell population, human CD33+ cell population, and human CD56+ cell population; 2) The determination of the logic gate and gate position is shown in the figure Shown in 7: First delineate the cell population, P1 gate; the cell population derived from the P1 gate removes the adherent cells, and it is the P2 gate; the cell population derived from the P2 gate is delineated with 7-AAD negative cells.
- the live cell population is P3 gate; source The cell populations in the P3 gate were delineated by NC mouse CD45+ (P4 gate) and human CD45+ cell populations (P5 gate); the cell populations derived from the P5 gate were delineated by NC human CD33+ (P11 gate) and human CD56+ cell populations (P13 gate) ; Cell populations derived from gate P5 were delineated with NC for human CD19+ (gate 10) and human CD3+ cell populations (gate P12).
- the transplantation efficiency of human hematopoietic stem cells is expressed by the proportion of human CD45 cells, and the calculation method is human CD45%/(human CD45%+mouse CD45%).
- Fig. 8A show that the bone marrow transplantation efficiency of the AG1296-treated hematopoietic stem cells at week 18 was significantly higher than that of the Mock group and the SR1 group under the condition of the same amount of cells in the initial culture of mouse transplantation.
- Figure 8B showed that the proportion of cells of each lineage formed by the differentiation of hematopoietic stem cells treated with AG1296 was not significantly different from the Mock group and the SR1 group, and the ability of hematopoietic stem cells treated with AG1296 to differentiate into cells of each lineage was normal.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
抗体名称 | 厂家 | 货号 |
APC/Cy7 anti-human CD45 | Biolegend | 304014 |
APC anti-human CD38 | Biolegend | 356606 |
Brilliant Violet 510™;anti-human CD34 | Biolegend | 343528 |
PE anti-human CD90(Thy1) | Biolegend | 328110 |
FITC anti-human CD45RA | Biolegend | 304106 |
APC Mouse IgG2a,κIsotype Ctrl | Biolegend | 400220 |
APC/Cyanine7Mouse IgG1,κIsotype Ctrl | Biolegend | 400128 |
PE Mouse IgG2a,κIsotype Ctrl | Biolegend | 400212 |
FITC Mouse IgG2b,κIsotype Ctrl | Biolegend | 402208 |
Brilliant Violet 510™;Mouse IgG2a,κIsotype Ctrl | Biolegend | 400268 |
组别 | 小分子抑制剂使用浓度 |
Mock | NA |
SR1 | 5μM |
AG1296 | 1μM |
抗体名称 | 厂家 | 货号 |
FITC anti-mouse CD45 | Biolegend | 103108 |
APC/Cy7 anti-human CD45 | Biolegend | 304014 |
Brilliant Violet 510 TManti-human CD3 | Biolegend | 300448 |
PE anti-human CD19 | Biolegend | 363004 |
Brilliant Violet 421 TManti-human CD33 | Biolegend | 303416 |
APC anti-human CD56 | Biolegend | 304610 |
7-AAD Viability Staining Solution | Biolegend | 420404 |
Claims (31)
- 一种用于扩增并维持造血干细胞(hematopoietic stem cells,HSCs)自我更新能力和分化潜能的培养基组合物,其包括造血干细胞培养基和PDGFR靶点的小分子抑制剂。
- 根据权利要求1所述的组合物,其中,所述PDGFR靶点的小分子抑制剂选自下述中的一种或多种:AG1296、PDGFR inhibitor 1、Imatinib、PP121、Ponatinib、Axitinib、Trapidil和Erdafitinib,优选为AG1296。
- 根据权利要求1或2所述的培养基组合物,其中,所述造血干细胞培养基包含:1)基础培养基(优选无血清的基础培养基);2)生长因子;和/或3)细胞因子。
- 根据权利要求3所述的培养基组合物,其中,所述生长因子或细胞因子选自如下的一种或多种:生长因子Flt-3L、生长因子SCF、生长因子TPO和白细胞介素IL-6。
- 根据权利要求4所述的培养基组合物,其中所述生长因子或细胞因子在所述培养基组合物中的浓度如下所示:所述生长因子Flt-3L的浓度为10-110ng/ml,优选为50-100ng/ml;所述生长因子SCF的浓度为10-110ng/ml,优选为50-100ng/ml;所述生长因子TPO的浓度为10-110ng/ml,优选为50-100ng/ml;所述白细胞介素IL-6的浓度为1-50ng/ml,优选为1-20ng/ml。
- 根据权利要求1-5中任一项所述的培养基组合物,其中,所述PDGFR靶点的小分子抑制剂在所述培养基组合物中的浓度为0.1-100μM,优选为0.5-50μM,进一步优选为1-10μM。
- 根据权利要求1-6中任一项所述的培养基组合物,其中,所述HSCs来源于骨髓、动员外周血、脐带血、冻存复苏的HSCs或经过基因编辑改造的HSCs。
- 一种促进HSCs扩增并维持HSCs自我更新能力的方法,包括在含有PDGFR靶点的小分子抑制剂的培养基组合物中体外培养HSCs。
- 根据权利要求8所述的方法,其中,所述PDGFR靶点的小分子抑制剂选自下述中的一种或多种:AG1296、PDGFR inhibitor 1、Imatinib、PP121、 Ponatinib、Axitinib、Trapidil和Erdafitinib,优选为AG1296。
- 根据权利要求8或9所述的方法,其中,所述造血干细胞培养基包含:1)基础培养基(优选无血清的基础培养基);2)生长因子;和/或3)细胞因子。
- 根据权利要求10所述的方法,其中,所述生长因子或细胞因子选自如下的一种或多种:Flt-3L、生长因子SCF、生长因子TPO和白细胞介素IL-6。
- 根据权利要求11所述的方法,其中所述生长因子或细胞因子在所述培养基组合物中的浓度如下所示:所述生长因子Flt-3L的浓度为10-110ng/ml,优选为50-100ng/ml;所述生长因子SCF的浓度为10-110ng/ml,优选为50-100ng/ml;所述生长因子TPO的浓度为10-110ng/ml,优选为50-100ng/ml;所述白细胞介素IL-6的浓度为1-50ng/ml,优选为1-20ng/ml。
- 根据权利要求8-12任一项所述的方法,其中,所述PDGFR靶点的小分子抑制剂在所述培养基组合物中的浓度为0.1-100μM,优选为0.5-50μM,进一步优选为1-10μM。
- 根据权利要求8-13中任一项所述的方法,其中,所述HSCs来源于骨髓、动员外周血、脐带血、冻存复苏的HSCs或经过基因编辑改造的HSCs。
- 根据权利要求8-14中任一项所述的方法,其中,体外培养时间为约4-21天,优选为约6-15天,进一步优选为约6-10天,最优选为约6-8天。
- 根据权利要求8-15中任一项所述的方法,其中,体外培养后,CD34+表型的HSCs细胞数占全部细胞中的比例为40-85%,优选为60-85%,进一步优选为75-80%。
- 根据权利要求8-16中任一项所述的方法,其中,体外培养后,CD34+CD90+表型的HSCs细胞数占全部细胞中的比例为6-15%,优选为8-15%,进一步优选为8-12%。
- 根据权利要求8-17中任一项所述的方法,其中,体外培养后,CD34+CD90+CD45RA-表型的HSCs细胞数占全部细胞中的比例为2-10%,优选为2-6%,进一步优选为4-5%。
- 根据权利要求8-18中任一项所述的方法,其中,体外培养后,CD34+CD45+CD90+CD45RA-CD38-表型的HSCs的细胞数占全部细胞中的 比例为2-5%,优选为2.5-4%。
- 一种HSCs输注液,其中,CD34+表型的HSCs细胞数占全部细胞总数的比例为40-85%,优选为60-85%,进一步优选为75-80%。
- 根据权利要求20所述的HSCs输注液,其中,CD34+CD90+表型的HSCs细胞数占全部细胞中的比例为6-15%,优选为8-15%,进一步优选为8-12%。
- 根据权利要求20或21所述的HSCs输注液,其中,CD34+CD90+CD45RA-表型的HSCs细胞数占全部细胞中的比例为2-10%,优选为2-6%,进一步优选为4-5%。
- 根据权利要求20-22任一项所述的HSCs输注液,其中,CD34+CD45+CD90+CD45RA-CD38-表型的HSCs的细胞占全部细胞中的比例为2-5%,优选为2.5-4%。
- 根据权利要求20-23任一项所述的HSCs输注液,其通过权利要求8-19任一项的方法获得。
- 一种给有需要的个体补充血细胞的方法,包括将权利要求20-24任一项所述的HSCs输注液输注给所述个体。
- 根据权利要求25的方法,其中所述HSCs输注液输注给所述个体后,所述HSCs在所述个体中定植、分化为血细胞。
- 根据权利要求25或26的方法,其中所述个体为罹患出血、贫血、癌症、白血病、自身免疫病、病毒或细菌感染的个体。
- PDGFR靶点的小分子抑制剂在促进HSCs扩增并维持HSCs自我更新能力中的用途,优选的,所述PDGFR靶点的小分子抑制剂选自下述中的一种或多种:AG1296、PDGFR inhibitor 1、Imatinib、PP121、Ponatinib、Axitinib、Trapidil和Erdafitinib,优选为AG1296。
- 一种预防或治疗个体疾病的方法,包括将权利要求20-24任一项所述的HSCs输注液输注给所述个体。
- 根据权利要求20-24任一项所述的HSCs输注液在制备预防或治疗疾病的药物中的用途。
- 根据权利要求30所述的用途,其中,所述疾病为需要补充血细胞的疾病。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180085998.8A CN116635045A (zh) | 2020-12-28 | 2021-12-28 | 用于扩增并维持HSCs自我更新能力和分化潜能的培养基组合物及其应用 |
US18/270,181 US20240058387A1 (en) | 2020-12-28 | 2021-12-28 | Culture medium composition for amplifying and maintaining self-renewal capacity and differentiation potential of hscs and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2020/140172 | 2020-12-28 | ||
CN2020140172 | 2020-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022143675A1 true WO2022143675A1 (zh) | 2022-07-07 |
Family
ID=82259076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/142127 WO2022143675A1 (zh) | 2020-12-28 | 2021-12-28 | 用于扩增并维持HSCs自我更新能力和分化潜能的培养基组合物及其应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240058387A1 (zh) |
CN (2) | CN114752563A (zh) |
TW (1) | TW202242096A (zh) |
WO (1) | WO2022143675A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116445408B (zh) * | 2023-05-22 | 2024-02-02 | 呈诺再生医学科技(北京)有限公司 | LSD1抑制剂在促进iPSC向HSC分化和HSC干性维持中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105713879A (zh) * | 2014-12-01 | 2016-06-29 | 顺昊细胞生物技术(天津)股份有限公司 | 一种用于脐带血造血干细胞扩增的培养体系及其应用 |
CN110461876A (zh) * | 2017-01-20 | 2019-11-15 | 美真达治疗公司 | 用于耗尽cd137+细胞的组合物和方法 |
CN110713979A (zh) * | 2018-07-11 | 2020-01-21 | 深圳华云生物技术有限公司 | 一种cd34+造血干细胞的培养方法 |
-
2021
- 2021-12-28 CN CN202111630520.7A patent/CN114752563A/zh active Pending
- 2021-12-28 US US18/270,181 patent/US20240058387A1/en active Pending
- 2021-12-28 CN CN202180085998.8A patent/CN116635045A/zh active Pending
- 2021-12-28 WO PCT/CN2021/142127 patent/WO2022143675A1/zh active Application Filing
- 2021-12-28 TW TW110149151A patent/TW202242096A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105713879A (zh) * | 2014-12-01 | 2016-06-29 | 顺昊细胞生物技术(天津)股份有限公司 | 一种用于脐带血造血干细胞扩增的培养体系及其应用 |
CN110461876A (zh) * | 2017-01-20 | 2019-11-15 | 美真达治疗公司 | 用于耗尽cd137+细胞的组合物和方法 |
CN110713979A (zh) * | 2018-07-11 | 2020-01-21 | 深圳华云生物技术有限公司 | 一种cd34+造血干细胞的培养方法 |
Non-Patent Citations (2)
Title |
---|
A. E. BOITANO, L. DE LICHTERVELDE, J. L. SNEAD, M. P. COOKE, P. G. SCHULTZ: "An image-based screen identifies a small molecule regulator of megakaryopoiesis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 35, 28 August 2012 (2012-08-28), pages 14019 - 14023, XP055122887, ISSN: 00278424, DOI: 10.1073/pnas.1212545109 * |
LIM SUNG-EUN; ESAIN VIRGINIE; KWAN WANDA; THEODORE LINDSAY N.; CORTES MAURICIO; FROST ISAURA M.; LIU SARAH Y.; NORTH TRISTA E.: "HIF1α-induced PDGFRβ signaling promotes developmental HSC production via IL-6 activation", EXPERIMENTAL HEMATALOGY, vol. 46, 15 October 2016 (2016-10-15), US , pages 83 - 95+6, XP029883100, ISSN: 0301-472X, DOI: 10.1016/j.exphem.2016.10.002 * |
Also Published As
Publication number | Publication date |
---|---|
CN114752563A (zh) | 2022-07-15 |
TW202242096A (zh) | 2022-11-01 |
CN116635045A (zh) | 2023-08-22 |
US20240058387A1 (en) | 2024-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
To et al. | A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells | |
JP2007536936A (ja) | 幹細胞集団および使用方法 | |
AU2009290134B2 (en) | Expansion of haemopoietic precursors | |
RU2757818C2 (ru) | Способы и композиции для трансплантации стволовых клеток | |
CN112980789A (zh) | 扩增造血干细胞的小分子化合物及其组合 | |
AU2021210307A1 (en) | Serum-free medium and culturing method suited for culturing blood cells such as human hematopoietic stem cells | |
KR20020013480A (ko) | 사람 뇌의 내피세포 및 성장배지 및 원시 cd34+cd38-골수 간세포의 증가방법 | |
CN114075547A (zh) | 扩增造血干细胞的方法及其组合物 | |
WO2022143675A1 (zh) | 用于扩增并维持HSCs自我更新能力和分化潜能的培养基组合物及其应用 | |
JPH06508528A (ja) | インビトロ由来ヒト好中球前駆体細胞 | |
US20040248295A1 (en) | Method for expanding hematopoietic stem cells | |
WO2005071064A1 (ja) | 造血幹細胞及び造血前駆細胞の増幅方法 | |
WO2021121266A1 (zh) | 扩增造血干细胞的小分子化合物及其组合 | |
RU2360965C1 (ru) | СПОСОБ УВЕЛИЧЕНИЯ КОЛИЧЕСТВА ГЕМОПОЭТИЧЕСКИХ НЕДИФФЕРЕНЦИРОВАННЫХ СТВОЛОВЫХ КЛЕТОК ПАЦИЕНТА ex vivo | |
JPH10136978A (ja) | 造血幹細胞の培養方法 | |
WO2021131261A1 (ja) | 細胞群及びその取得方法 | |
JP2005527223A (ja) | サイトカインフリーでの前駆細胞の増殖および維持 | |
KR100999905B1 (ko) | 생착능이 증가된 조혈줄기세포의 제조방법 | |
JP6706836B2 (ja) | 単核球培養用無血清培地 | |
KR101149007B1 (ko) | 생착능이 증가된 조혈줄기세포의 제조방법 | |
CN116042522A (zh) | 一种基于仿生微载体的规模化扩增人造血干细胞方法 | |
WO1999000486A1 (en) | Compositions and methods for inducing the development and differentiation of hemopoietic stem cells | |
Holyoake et al. | CD34 selection and ex vivo expansion of haemopoietic progenitor cells: a review of laboratory methodology | |
JP2007508023A (ja) | 間葉幹細胞由来の血液生成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21914409 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180085998.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18270181 Country of ref document: US Ref document number: 2023539924 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21914409 Country of ref document: EP Kind code of ref document: A1 |